ASBP

Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) is a biotechnology company that went public in April 2022, specializing in advanced diagnostic solutions and molecular testing technologies. Founded as a research-focused entity, the company has positioned itself in the rapidly evolving field of precision medicine, where genetic and biochemical analysis plays an increasingly critical role in healthcare decision-making. Currently, Aspire Biopharma remains in the pre-revenue development stage, focusing on developing high-precision diagnostic assays while burning through cash as it works toward commercialization of its testing platforms.